Physician profile
Albert Leung
NPI 1346356755
$31,488.48
in general payments reported to CMS, 2019-2025
42 companies · $4,043 in 2025
The $4,043 reported for 2025 was more than what 97% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,174 · 2020: $3,721 · 2021: $4,746 · 2022: $5,575 · 2023: $3,298 · 2024: $3,933 · 2025: $4,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,273.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,593.13 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Abbvie INC. | $3,066.02 | 2019-2025 | |
| Novo Nordisk INC | $2,144.80 | 2019-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $2,111.84 | 2019-2022 | |
| Amgen INC. | $2,054.75 | 2019-2025 | Tavneos, Repatha, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,844.90 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $1,685.05 | 2021-2025 | |
| Lilly USA, LLC | $1,416.84 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,242.18 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $1,141.05 | 2019-2024 | Nucala, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $1,044.81 | 2019-2024 | |
| Allergan, INC. | $878.37 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $877.35 | 2023-2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $732.58 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $718.73 | 2019-2025 | Ingrezza |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Leung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.